Isabella Ciccone, MPH

Michelle Chen, PhD, a neuropsychologist at Rutgers University, talked about the motivations behind her most recent published study on incorporating keystroke dynamics in MS cognition.

The FDA lifted its clinical hold on Astellas Pharma's FORTIS trial for evaluating AT845 in adults with late-onset Pompe disease.

In the letter, the FDA specifically required that Eli Lilly provide data from at least 100 patients who received a minimum of 12 months of continuous treatment with donanemab.

A systematic review revealed inconsistencies in the literature for assessing subjective cognitive complaints in cognitively normal patients with Parkinson disease.

Results from on ongoing phase 1 trial showed a favorable safety profile with CT103A in patients with NMOSD.

Sharon Cohen, MD, FRCPC, provided an investigator perspective on the use of lecanemab for patients with Alzheimer disease and what the clinician community can take away from the trials.

Glymphatic function demonstrated no significant difference in patients with type 1 and type 2 narcolepsy in comparison with healthy controls.

Sharon Cohen, MD, FRCPC, offered her insight on the significance of the lecanemab approval and what it means for patients with Alzheimer disease.

Ryan Case, PhD, head of clinical medical affairs at NeuroDerm, spoke about the main findings from the phase 3 BouNDless trial of ND0612 for Parkinson disease.

A rare case of neuromyelitis optica was reported with a woman aged in her 70s from Iran who experienced neurological symptoms after COVID-19 vaccination.

A questionnaire showed that adolescents with narcolepsy and parents prefer to receive details on narcolepsy at the time of diagnosis from a healthcare provider.

A population-based incident of Parkinson disease cases showed patients were more likely to develop PD dementia in 10 years with a lower level of lysosomal enzyme glucocerebrosidase activity.

A study reported a rare case of seronegative NMOSD with a middle-aged man in Nepal who did not improve in clinical status and performance after given treatment.

After 2 months of treatment, findings showed more improvement in anxiety and mental status with acupuncture in patients with Parkinson Disease than those on sham acupuncture.

UCB’s rozanolixizumab received priority review on its biologic license application by FDA and expects feedback during the second quarter of 2023.

Anand Patel, MD, CPI, chief medical officer at Conquest Research, spoke about the findings from the phase 2 RELIEF-DPN-1 trial assessing LX9211 in sleep health.

A rare case report illustrated an 80-year-old man with aquaporin-4 antibody-positive NMOSD following a second dose of the Pfizer-BioNTech COVID-19 mRNA BNT162b2 vaccine.

A recent congressional investigation report on Biogen’s aducanumab and the FDA’s approval process recommended Biogen to fulfill their responsibility for individuals who rely on their treatments.

Results from a prospective study demonstrated a higher visual field defect in patients with neuromyelitis optica spectrum disorder-optic neuritis compared with those who had idiopathic optic neuritis.

The past year has provided great steps forward in sleep science, and coupled with the lingering difficulties in care and the COVID-19 pandemic’s effects, the field is coming to a head to make sleep health a public health priority.

A review of randomized controlled trials on balance interventions highlighted the effects for improved mobility and balance in multiple sclerosis.

An updated literature review provided data to assist with the revisioning of quality measures in in clinical practice for adults with obstructive sleep apnea.

A recent review from the National MS Society revealed eight themes based on previous clinical trials focused on exercise and physical activity in MS.

Findings from a recent randomized study demonstrated effective sleep maintenance of insomnia, as shown by increased sleep time and reduced awakenings, with low concentration of carbon dixoide.

A recent review suggests that children might be affected by specific types of insomnia and that their treatment should be more suitable to their classified insomnia phenotype.

A recent phase 2 study showed a significant decline in wakefulness after sleep onset across both doses of sunobinop for individuals with insomnia recovery from alcohol use disorder.

In a recent time-to-event analysis based on two clinical trials of patients with Dravet syndrome results demonstrated an overall reduction in seizure burden with fenfluramine.

A qualitative study presented at the 2022 AES annual meeting showed that effective communication between clinicians and caregivers of patients with dravet syndrome improves care.

Recent findings presented in a poster at the 2022 AES revealed that higher mortality and shorter lifespans were associated with patients with dementia who have active seizures.

A retrospective observation study presented as a poster at the 2022 AES annual meeting revealed that youth with focal epilepsy were more at risk for suicidal ideation when there is a delay in receiving a diagnosis.